Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
David J. Sullivan, Massimo Franchini, Michael J. Joyner, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 77

Showing 51-75 of 77 citing articles:

Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China
Jingyun Tang, Humin Liu, Qing Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Tanaporn Meejun, Karan Srisurapanont, Kasama Manothummetha, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5624-5636
Open Access | Times Cited: 3
Convalescent Plasma Versus Hyperimmune Immunoglobulins
Daniele Focosi, Massimo Franchini, Emanuele Nicastri, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 9, pp. 1356-1357
Closed Access | Times Cited: 3
Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity
Max J. Bedding, Charlotte Franck, Jason Johansen‐Leete, et al.
ACS Chemical Biology (2023) Vol. 19, Iss. 1, pp. 141-152
Closed Access | Times Cited: 3
The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
Amanda M. Buck, Amelia N. Deitchman, Saki Takahashi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?
William A. Werbel, Ethel D. Weld, Sonali Advani, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 1, pp. 32-37
Open Access | Times Cited: 2
Immunoinformatics and MD-simulation data suggest that Omicron spike epitopes are more interacting to IgG via better MHC recognition than Delta variant
Aniket Sarkar, Dipannita Santra, Anindya Sundar Panja, et al.
International Immunopharmacology (2023) Vol. 123, pp. 110636-110636
Closed Access | Times Cited: 2
Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory
Patrizio Caturegli, Oliver Laeyendecker, Aaron A.R. Tobian, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 2
Is convalescent plasma still useful as a covid treatment?
Katharine Lang
BMJ (2023), pp. p2185-p2185
Open Access | Times Cited: 2
Understanding the parameters guiding the best practice for treating B‐cell‐depleted patients with COVID‐19 convalescent plasma therapy
David Gachoud, Claire Bertelli, Nathalie Rufer
British Journal of Haematology (2022) Vol. 200, Iss. 2
Open Access | Times Cited: 4
SARS-CoV-2 Neutralizing Antibodies in Three African Countries Following Multiple Distinct Immune Challenges
Diary Juliannie Ny Mioramalala, Rila Ratovoson, Paul Alain Tagnouokam‐Ngoupo, et al.
(2024)
Open Access
Clinical efficacy of SARS‐CoV‐2 Omicron‐neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency
Michael Karbiener, Gerhard Kindle, Isabelle Meyts, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 6
Open Access
Systematic analysis of SARS-CoV-2 Omicron subvariants’ impact on B and T cell epitopes
Ruba Al Khalaf, Anna Bernasconi, Pietro Pinoli
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0307873-e0307873
Open Access
CONVALESCENT PLASMA THERAPY FOR COVID-19 – DONOR SELECTION STRATEGIES AND ESTABLISHMENT OF A PLASMA BANK
Mikael Kajova, Tamim Khawaja, Iris Levonen, et al.
New Microbes and New Infections (2024) Vol. 62, pp. 101525-101525
Open Access
Wastewater sequencing from a rural community enables identification of widespread adaptive mutations in a SARS-CoV-2 Alpha variant
Michael J. Conway, Michael P. Novay, Carsten M. Pusch, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
Caroline Mcleod, Michael Dymock, Katie L. Flanagan, et al.
Journal of Infection (2024) Vol. 89, Iss. 6, pp. 106346-106346
Open Access
Novel approaches for preventing COVID-19 infection in immunocompromised patients with hematologic malignancies
Shmuel Shoham, Daniele Focosi, Massimo Franchini, et al.
Expert Review of Hematology (2024)
Closed Access
Towards the identification of the correct place for convalescent plasma among COVID-19 therapies
Massimo Franchini, Daniele Focosi
Infectious Diseases (2024) Vol. 56, Iss. 6, pp. 421-422
Open Access
Antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID‐19 infection
Dorit Blickstein, Marina Izak, Talia Filipovich‐Rimon, et al.
Vox Sanguinis (2023) Vol. 118, Iss. 7, pp. 517-522
Closed Access | Times Cited: 1
Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021
Yi-Chan Lin, David H. Evans, Ninette F Robbins, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 4
Open Access | Times Cited: 1
Convalescent plasma in oncohematological patients
Daniele Focosi, Massimo Franchini, Michael J. Joyner, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 208-209
Open Access | Times Cited: 2
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
Rada M. Grubovic Rastvorceva, Sedula Useini, Milena Stevanovic, et al.
Life (2022) Vol. 12, Iss. 10, pp. 1565-1565
Open Access | Times Cited: 1
SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape
Daniele Focosi, Fabrizio Maggi
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2488-2488
Open Access
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Han-Sol Park, Anna Yin, Caelan Barranta, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Current advances in 2022: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee
Ryan A. Metcalf, Claudia S. Cohn, Sara Bakhtary, et al.
Transfusion (2023) Vol. 63, Iss. 8, pp. 1590-1600
Open Access

Scroll to top